In vitro assessment of the formation of ceftriaxone-calcium precipitates in human plasma

Journal of Pharmaceutical Sciences

Volumn 100, Issue 6, 2011, Pages 2300-2310

  Schmutz, Hans Rudolf ^a   Detampel, Pascal ^a,b   Bühler, Theo ^a   Büttler, André ^a   Gygax, Benjamin ^a   Huwyler, Jörg ^b  

^a UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Calcium; Ceftriaxone; FTIR; HPLC; In vitro; Plasma; Precipitation; Solubility; Spectroscopy

Indexed keywords

CALCIUM; CEFTRIAXONE;

ARTICLE; DRUG BINDING; DRUG DETERMINATION; DRUG SOLUBILITY; HUMAN; PLASMA; PRECIPITATION; THERMODYNAMICS;

EID: 79954584488     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22466     Document Type: Article

References (62)

1. Perry TR, Schentag JJ. 2001. Clinical use of ceftriaxone: A pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding. Clin Pharmacokinet 40:685-694.
2. Lamb HM, Ormrod D, Scott LJ, Figgitt DP. 2002. Ceftriaxone: An update of its use in the management of community-acquired and nosocomial infections. Drugs 62:1041-1089.
3. The Merck Index. 2001. Merck index. 13th ed. Rahway, New Jersey: Merck Research Laboratories.
4. Shiffman ML, Keith FB, Moore EW. 1990. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 99:1772-1778.
5. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T. 2001. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 47:421-429.
6. Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ. 1982. Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults. Antimicrob Agents Chemother 22:816-823.
7. Findlay CD, Brown RM, Allcock JE, Lowe PA, Wise R. 1982. A study of the relationship between dose and pharmacokinetics of ceftriaxone. J Antimicrob Chemother 9:57-62.
8. Hayton WL, Stoeckel K. 1986. Age-associated changes in ceftriaxone pharmacokinetics. Clin Pharmacokinet 11:76-86.
9. Martin E, Koup JR, Paravicini U, Stoeckel K. 1984. Pharmacokinetics of ceftriaxone in neonates and infants with meningitis. J Pediatr 105:475-481.
10. Patel IH, Kaplan SA. 1984. Pharmacokinetic profile of ceftriaxone in man. Am J Med 77:17-25.
11. McCracken GH, Siegel JD, Threlkeld N, Thomas M. 1983. Ceftriaxone pharmacokinetics in newborn infants. Antimicrob Agents Chemother 23:341-343.
12. Schaad UB, Hayton WL, Stoeckel K. 1985. Single-dose ceftriaxone kinetics in the newborn. Clin Pharmacol Ther 37:522-528.
13. Schaad UB, Stoeckel K. 1982. Single-dose pharmacokinetics of ceftriaxone in infants and young children. Antimicrob Agents Chemother 21:248-253.
14. Bradley JS, Wassel RT, Lee L, Nambiar S. 2009. Intravenous ceftriaxone and calcium in the neonate: Assessing the risk for cardiopulmonary adverse events. Pediatrics 123:e609-e613.
15. Monte SV, Prescott WA, Johnson KK, Kuhman L, Paladino JA. 2008. Safety of ceftriaxone sodium at extremes of age. Expert Opin Drug Saf 7:515-523.
16. Purdum PP, Shiffman ML, Moore EW. 1992. In vivo studies of biliary ceftriaxone excretion and solubility in guinea pig hepatic bile. J Lab Clin Med 120:604-613.
17. Park HZ, Lee SP, Schy AL. 1991. Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology 100:1665-1670.
18. Avci Z, Koktener A, Uras N, Catal F, Karadag A, Tekin O, Degirmencioglu H, Baskin E. 2004. Nephrolithiasis associated with ceftriaxone therapy: A prospective study in 51 children. Arch Dis Child 89:1069-1072.
19. Nordin BE. 1990. Calcium homeostasis. Clin Biochem 23:3-10.
20. Roche Pharmaceuticals. 2010. Rocephin [Package Insert]. Available from: Accessed Date: January 5, 2011.
21. Granich GG, Krogstad DJ. 1987. Ion pair high-performance liquid chromatographic assay for ceftriaxone. Antimicrob Agents Chemother 31:385-388.
22. Trautmann KH, Haefelfinger P. 1981. Determination of the cephalosporin Ro 13-9904 in plasma, urine, and bile by means of ion-pair reversed phase chromatography. J High Resolut Chromatogr 4:54-59.
23. Nakai Y, Tokuyama E, Yoshida M, Uchida T. 2009. Incompatibility of ceftriaxone sodium with calcium-containing products. Yakugaku Zasshi 129:1385-1392.
24. Steadman E, Raisch DW, Bennett CL, Esterly JS, Becker T, Postelnick M, McKoy JM, Trifilio S, Yarnold PR, Scheetz MH. 2010. Evaluation of a potential clinical interaction between ceftriaxone and calcium. Antimicrob Agents Chemother 54:1534-1540.
25. Puzovic M, Hardy G. 2008. Comment: Clinical pharmaceutics and calcium ceftriaxone. Ann Pharmacother 42:1914.
26. Nakai Y, Tokuyama E, Yoshida M, Uchida T. 2010. Prediction of incompatibility of ceftriaxone sodium with calcium ions using the ionic product. Yakugaku Zasshi 130:95-102.
27. Parker RI. 2010. Thrombosis in the pediatric population. Crit Care Med 38:S71-S75.
28. Rapp RP, Kuhn R. 2007. Clinical pharmaceutics and calcium ceftriaxone. Ann Pharmacother 41:2072.
29. Gin AS, Wheaton H, Dalton B. 2008. Clinical pharmaceutics and calcium-ceftriaxone. Ann Pharmacother 42:450-451.
30. ICH Expert Working Group. 2005. ICH harmonised tripartite guideline; Validation of analytical procedures: Text and methodology Q2(R1). Available from: Accessed Date: January 5, 2011.
31. Burritt MF, Slockbower JM, Forsman RW, Offord KP, Bergstralh EJ, Smithson WA. 1990. Pediatric reference intervals for 19 biologic variables in healthy children. Mayo Clin Proc 65:329-336.
32. Sitzmann FC. 1976. Normalwerte. München, Germany: Hans Marseille Verlag.
33. Brodersen R, Robertson A. 1989. Ceftriaxone binding to human serum albumin: Competition with bilirubin. Mol Pharmacol 36:478-483.
34. Owens NJ, Nightingale CH, Quintiliani R, Pyrtek LJ. 1987. Concentrations of ceftriaxone in gallbladder wall, bile, and serum in patients undergoing cholecystectomy. Clin Pharm 6:967-968.
35. Thode J. 1985. The calcium ion activity and the standardized excretion rate of calcium in urine of healthy adults. Scand J Clin Lab Invest 45:327-334.
36. Shiffman ML, Sugerman HJ, Kellum JM, Moore EW. 1992. Calcium in human gallbladder bile. J Lab Clin Med 120:875-884.
37. Gleeson D, Hood KA, Murphy GM, Dowling RH. 1992. Calcium and carbonate ion concentrations in gallbladder and hepatic bile. Gastroenterology 102:1707-1716.
38. Sutor DJ, Wilkie LI, Jackson MJ. 1980. Ionised calcium in pathological human bile. J Clin Pathol 33:86-88.
39. Xia Y, Lambert KJ, Schteingart CD, Gu JJ, Hofmann AF. 1990. Concentrative biliary secretion of ceftriaxone. Inhibition of lipid secretion and precipitation of calcium ceftriaxone in bile. Gastroenterology 99:454-465.
40. Wheeler HO. 1971. Concentrating function of the gallbladder. Am J Med 51:588-595.
41. Bonnet JP, Abid L, Dabhar A, Lévy A, Soulier Y, Blangy S. 2000. Early biliary pseudolithiasis during ceftriaxone therapy for acute pyelonephritis in children: A prospective study in 34 children. Eur J Pediatr Surg 10:368-371.
42. Prince JS, Senac MO. 2003. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child. Pediatr Radiol 33:648-651.
43. Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. 1988. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet 2:1411-1413.
44. Araz N, Okan V, Demirci M, Araz M. 2007. Pseudolithiasis due to ceftriaxone treatment for meningitis in children: Report of 8 cases. Tohoku J Exp Med 211:285-290.
45. Becker CD, Fischer RA. 2009. Acute cholecystitis caused by ceftriaxone stones in an adult. Case Rep Med 2009:132452.
46. Ohya T, Schwarzendrube J, Busch N, Gresky S, Chandler K, Takabayashi A, Igimi H, Egami K, Holzbach RT. 1993. Isolation of a human biliary glycoprotein inhibitor of cholesterol crystallization. Gastroenterology 104:527-538.
47. Rege RV, Dawes LG, Moore EW. 1989. Canine common duct and gallbladder bile contain antinucleating factors that inhibit CaCO3 precipitation. J Lab Clin Med 113:642-650.
48. Moore EW. 1990. Biliary calcium and gallstone formation. Hepatology 12:206S-214S; discussion 214S-218S.
49. Brouwers J, Brewster ME, Augustijns P. 2009. Supersaturating drug delivery systems: The answer to solubility-limited oral bioavailability? J Pharm Sci 98:2549-2572.
50. Portmann GA, Simmons DM. 1995. Microscopic determination of drug solubility in plasma and calculation of injection rates with a plasma circulatory model to prevent precipitation on intravenous injection. J Pharm Biomed Anal 13:1189-1193.
51. Cox JW, Sage GP, Wynalda MA, Ulrich RG, Larson PG, Su CC. 1991. Plasma compatibility of injectables: Comparison of intravenous U-74006F, a 21-aminosteroid antioxidant, with Dilantin brand of parenteral phenytoin. J Pharm Sci 80:371-375.
52. Stoeckel K, McNamara PJ, Brandt R, Plozza-Nottebrock H, Ziegler WH. 1981. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther 29:650-657.
53. Popick AC, Crouthamel WG, Bekersky I. 1987. Plasma protein binding of ceftriaxone. Xenobiotica 17:1139-1145.
54. Li P, Vishnuvajjala R, Tabibi SE, Yalkowsky SH. 1998. Evaluation of in vitro precipitation methods. J Pharm Sci 87:196-199.
55. Yalkowsky SH, Valvani SC, Johnson BW. 1983. In vitro method for detecting precipitation of parenteral formulations after injection. J Pharm Sci 72:1014-1017.
56. Belliard CR, Sibille G. 2007. Anaphylactoid shock or precipitation of calcium-ceftriaxone in a premature newborn. A case report. Arch Pediatr 14:199-200.
57. Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. 1997. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health Syst Pharm 54:1295-1300.
58. Hardy G, Messing B. 2005. Beyond the bag horizon. Nutrition 21:1179-1180.
59. Dalton BR, Zuege DJ, Shahpori R, Laupland KB. 2010. Concomitant ceftriaxone and high-concentration intravenous calcium therapy in adult critical care patients: A matched cohort study. Ann Pharmacother 44:1158-1163.
60. Dennery PA, Seidman DS, Stevenson DK. 2001. Neonatal hyperbilirubinemia. N Engl J Med 344:581-590.
61. 1994. Practice parameter: Management of hyperbilirubinemia in the healthy term newborn. American Academy of Pediatrics. Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia. Pediatrics 94:558-565.
62. Porter ML, Dennis BL. 2002. Hyperbilirubinemia in the term newborn. Am Fam Phys 65:599-606.